Stockreport

Endocyte Announces Enrollment of First Patient in Phase 3 VISION Trial of 177Lu-PSMA-617 in Prostate Cancer

ENDOCYTE  (ECYT) 
Last endocyte earnings: 11/7 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.endocyte.com/investor-relations
PDF WEST LAFAYETTE, Ind., June 05, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized can [Read more]